|
EP0173552B1
(en)
|
1984-08-24 |
1991-10-09 |
The Upjohn Company |
Recombinant dna compounds and the expression of polypeptides such as tpa
|
|
US5168062A
(en)
|
1985-01-30 |
1992-12-01 |
University Of Iowa Research Foundation |
Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
|
|
US5057540A
(en)
|
1987-05-29 |
1991-10-15 |
Cambridge Biotech Corporation |
Saponin adjuvant
|
|
NZ230747A
(en)
|
1988-09-30 |
1992-05-26 |
Bror Morein |
Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
|
|
WO1990014837A1
(en)
|
1989-05-25 |
1990-12-13 |
Chiron Corporation |
Adjuvant formulation comprising a submicron oil droplet emulsion
|
|
FR2705686B1
(fr)
|
1993-05-28 |
1995-08-18 |
Transgene Sa |
Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
|
|
US5851806A
(en)
|
1994-06-10 |
1998-12-22 |
Genvec, Inc. |
Complementary adenoviral systems and cell lines
|
|
EP0784690B1
(en)
|
1994-06-10 |
2006-08-16 |
Genvec, Inc. |
Complementary adenoviral vector systems and cell lines
|
|
US5965541A
(en)
|
1995-11-28 |
1999-10-12 |
Genvec, Inc. |
Vectors and methods for gene transfer to cells
|
|
US5846782A
(en)
|
1995-11-28 |
1998-12-08 |
Genvec, Inc. |
Targeting adenovirus with use of constrained peptide motifs
|
|
US5559099A
(en)
|
1994-09-08 |
1996-09-24 |
Genvec, Inc. |
Penton base protein and methods of using same
|
|
US5786464C1
(en)
|
1994-09-19 |
2012-04-24 |
Gen Hospital Corp |
Overexpression of mammalian and viral proteins
|
|
AUPM873294A0
(en)
|
1994-10-12 |
1994-11-03 |
Csl Limited |
Saponin preparations and use thereof in iscoms
|
|
DE69633565T3
(de)
|
1995-06-15 |
2013-01-17 |
Crucell Holland B.V. |
Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
|
|
US5837511A
(en)
|
1995-10-02 |
1998-11-17 |
Cornell Research Foundation, Inc. |
Non-group C adenoviral vectors
|
|
US5891690A
(en)
|
1996-04-26 |
1999-04-06 |
Massie; Bernard |
Adenovirus E1-complementing cell lines
|
|
CA2283253A1
(en)
|
1997-03-04 |
1998-09-11 |
Baxter International Inc. |
Adenovirus e1-complementing cell lines
|
|
US6020191A
(en)
|
1997-04-14 |
2000-02-01 |
Genzyme Corporation |
Adenoviral vectors capable of facilitating increased persistence of transgene expression
|
|
US5972650A
(en)
|
1997-06-26 |
1999-10-26 |
Brigham And Women's Hospital |
Tetracycline repressor regulated mammalian cell transcription and viral replication switch
|
|
US5981225A
(en)
|
1998-04-16 |
1999-11-09 |
Baylor College Of Medicine |
Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
|
|
US6113913A
(en)
|
1998-06-26 |
2000-09-05 |
Genvec, Inc. |
Recombinant adenovirus
|
|
ATE519854T1
(de)
|
1999-05-17 |
2011-08-15 |
Crucell Holland Bv |
Rekombinantes adenovirus auf basis von serotyp 48 (ad48).
|
|
US6913922B1
(en)
|
1999-05-18 |
2005-07-05 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
|
WO2003104467A1
(en)
|
2002-04-25 |
2003-12-18 |
Crucell Holland B.V. |
Means and methods for the production of adenovirus vectors
|
|
FR2794370B1
(fr)
|
1999-06-03 |
2003-10-17 |
Biovector Therapeutics |
Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
|
|
DE19955558C2
(de)
|
1999-11-18 |
2003-03-20 |
Stefan Kochanek |
Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
|
|
AU2002211490A1
(en)
|
2000-10-04 |
2002-04-15 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of using capsid protein from flaviviruses and pestiviruses
|
|
HU230198B1
(hu)
*
|
2000-11-23 |
2015-10-28 |
Bavarian Nordic A/S |
Módosított Vacciniavírus Ankara-variáns
|
|
WO2002088346A2
(en)
|
2001-05-01 |
2002-11-07 |
National Research Council Of Canada |
A system for inducible expression in eukaryotic cells
|
|
UA82479C2
(uk)
|
2002-05-16 |
2008-04-25 |
Бавариан Нордика А/С |
Міжгенні регіони як сайти вставки в геном модифікованого вірусу коров'ячої віспи ankara (mva)
|
|
SE0202110D0
(sv)
|
2002-07-05 |
2002-07-05 |
Isconova Ab |
Iscom preparation and use thereof
|
|
SE0301998D0
(sv)
|
2003-07-07 |
2003-07-07 |
Isconova Ab |
Quil A fraction with low toxicity and use thereof
|
|
EP1732598A4
(en)
*
|
2003-12-31 |
2009-08-26 |
Pharmexa Inc |
TRIGGERING CELLULAR IMMUNE RESPONSES TO THE HUMAN PAPILLOVIRUS USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
|
|
CN1922308A
(zh)
|
2004-02-23 |
2007-02-28 |
克鲁塞尔荷兰公司 |
病毒纯化方法
|
|
BRPI0517380A
(pt)
|
2004-11-08 |
2008-10-07 |
Chromagenics Bv |
molécula de dna, cassete de expressão, célula hospedeira, e, métodos para gerar uma célula hospedeira que expressa um polipeptìdeo de interesse e para produzir um polipeptìdeo de interesse
|
|
WO2007073513A2
(en)
|
2005-11-10 |
2007-06-28 |
Genvec, Inc. |
Method for propagating adenoviral vectors encoding inhibitory gene products
|
|
PT1996238T
(pt)
|
2006-02-28 |
2016-07-11 |
Vaxart Inc |
Vetores adenovíricos quiméricos e arncd como agonista de tlr3
|
|
WO2007104792A2
(en)
|
2006-03-16 |
2007-09-20 |
Crucell Holland B.V. |
Recombinant adenoviruses based on serotype 26 and 48, and use thereof
|
|
KR101514473B1
(ko)
*
|
2007-05-15 |
2015-04-22 |
트랜스진 에스.에이. |
다중 유전자 발현용 벡터
|
|
DE102008010954A1
(de)
|
2008-02-25 |
2009-08-27 |
Cichon, Günter, Prof.Dr. |
DNA-Vakzine zur Therapie und Prophylaxe von Gebärmutterhalskrebs und seinen prämalignen Vorstufen
|
|
EA019928B1
(ru)
|
2008-11-03 |
2014-07-30 |
Круселл Холланд Б.В. |
Способ получения аденовирусных векторов
|
|
GB0823497D0
(en)
|
2008-12-24 |
2009-01-28 |
Isis Innovation |
Immunogenic composition and use thereof
|
|
US8613936B2
(en)
|
2009-03-13 |
2013-12-24 |
Bavarian Nordic A/S |
Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements
|
|
US8394385B2
(en)
|
2009-03-13 |
2013-03-12 |
Bavarian Nordic A/S |
Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
|
|
PL2536829T3
(pl)
|
2010-02-15 |
2016-09-30 |
|
Sposób wytwarzania wektorów adenowirusowych Ad26
|
|
WO2013074501A1
(en)
|
2011-11-14 |
2013-05-23 |
Crucell Holland B.V. |
Heterologous prime-boost immunization using measles virus-based vaccines
|
|
EP2601968A1
(en)
|
2011-12-06 |
2013-06-12 |
Deutsches Krebsforschungszentrum |
HPV derived polynucleic acids for therapy
|
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
|
US9125870B2
(en)
|
2012-03-22 |
2015-09-08 |
Crucell Holland B.V. |
Vaccine against RSV
|
|
WO2014005643A1
(en)
*
|
2012-07-05 |
2014-01-09 |
Okairos Ag |
Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
|
|
MX380483B
(es)
*
|
2012-10-28 |
2025-03-12 |
Bavarian Nordic As |
Promotor pr13.5 para respuestas de anticuerpos y linfocitos t fuertes.
|
|
CA2959105C
(en)
*
|
2014-09-03 |
2023-10-17 |
Bavarian Nordic A/S |
Recombinant modified vaccinia virus ankara (mva) filovirus vaccine
|
|
EP3421046A1
(en)
*
|
2014-11-04 |
2019-01-02 |
Janssen Vaccines & Prevention B.V. |
Therapeutic hpv16 vaccines
|
|
HK1252967A1
(zh)
|
2015-08-20 |
2019-06-06 |
Janssen Vaccines & Prevention B.V. |
治疗性hpv18疫苗
|